Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: A candidate Lyme disease vaccine

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 904-914

  Edelman, Robert ^a   Palmer, Kathleen ^a   Russ, Karin G ^a   Secrest, Helen P ^a   Anna L Becker, Jo ^a   Bodison, Sacared A ^b   Perry, Judith G ^b   Sills, Alvin R ^b   Barbour, Alan G ^c   Luke, Catherine J ^c   Hanson, Mark S ^d   Stover, C Kendall ^d   Burlein, Jeanne E ^d   Bansal, Geetha P ^d   Connor, Edward M ^d   Koenig, Scott ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDIMMUNE   (United States)

Author keywords

BCG vectored vaccine; Lyme disease; Phase I vaccine trial

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; OUTER MEMBRANE PROTEIN;

ADULT; ARTICLE; BORRELIA BURGDORFERI; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; LYME DISEASE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SAFETY; TUBERCULIN TEST; VACCINATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BCG VACCINE; BORRELIA BURGDORFERI GROUP; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS; LYME DISEASE; MALE; MICE; TUBERCULIN TEST; VACCINES, SYNTHETIC;

EID: 0033605374     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00276-X     Document Type: Article

References (45)

1. Barletta R.G., Snapper B., Cirillo J.D., Connell N.D., Kim D.D., Jacobs W.R., Bloom B.R. Recombinant BCG as a candidate oral vaccine vector. Res Microbiol. 141:1990;931-939.
2. Stover C.K., de la Cruz V.F., Fuerst T.R., Burlein J.E., Benson L.T., Bennett L.T., Bansal G.P., Young J.F., Lee M.H., Hatfull G.F., et al. New use of BCG for recombinant vaccines. Nature. 351:1991;458-460.
3. Hanson MS, Bansal GP, Langermann S, Stover CK, Orme I. Efficacy and safety of live recombinant BCG vaccines. Dev. Biol. Stand. (Ed. Brown F) 84. 1995, p. 229-236.
4. Gheorghiu M., Lagranderie M.R., Gicquel B.M., Leclerc C.D. Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect Immun. 62:1994;4287-4295.
5. Stover C.K., Bansal G.P., Hanson M.S., Burlein J.E., Palaszynski S.R., Young J.F., Koenig S., Young D.B., Sadziene A., Barbour A.G. Protective immunity elicited by recombinant Bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein. A candidate Lyme disease vaccine. J Exp Med. 178:1993;197-209.
6. Langermann S., Palaszynski S., Sadziene A., Stover C.K., Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature. 372:1994;552-555.
7. Langermann S., Palaszynski S.R., Burlein J.E., Koenig S., Hanson M.S., Briles D.E., Stover C.K. Protective humoral response against pneumococcal infection in mice elicited by recombinant Bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med. 180:1994;2277-2286.
8. Cassatt DR, de la Cruz VF, Burlein JF, Young J, Koenig S, Stover CK. Protection of mice against tetanus challenge using an experimental tetanus vaccine based on recombinant BCG. In: Ginsberg H.S., Brown F., Chanock R.M., Lerner R.A., editors. Vaccines93. Modern Approaches to New Vaccines including Prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1993. p. 385-389.
9. Aldovini A., Young R.A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature. 351:1991;479-482.
10. Fuerst T.R., Stover C.K., de la Cruz V.F. Development of BCG as a live recombinant vector system: potential use as an HIV vaccine. Biotechnol. Ther. 2:1991;159-178.
11. Fennelly G.J., Flynn J.L., ter Meulen V., Liebert U.G., Bloom B.R. Recombinant Bacille Calmette-Guérin priming against measles. J Infect Dis. 172:1995;698-705.
12. Matsumoto S., Yanagi T., Ohara N., Wada N., Kanbara H., Yamada T. Stable expression and secretion of the B-cell epitope of rodent malaria from Mycobacterium bovis BCG and induction of long-lasting humoral response in mouse. Vaccine. 14:1996;54-60.
13. Kremer L., Riveau G., Baulard A., Capron A., Locht C. Neutralizing antibody responses elicited in mice immunized with Bacillus Calmette-Guérin producing the Schistosoma mansoni glutathione S-transferase. J Immunol. 156:1996;4309-4317.
14. Fikrig E., Telford I.I.I. S.R., Barthold S.W., Kantor F.S., Spielman A., Flavell R.A. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci USA. 89:1992;5418-5421.
15. Schaible U.E., Kramer M.D., Eichmann K., Modolell M., Museteanu C., Simon M.M. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci USA. 87:1990;3768-3772.
16. Ma J., Hine P.M., Clough E.R., Fish D., Coughlin R.T., Beltz G.A., Shew M.G. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine. 14:1996;1366-1374.
17. Golde W.T., Burkot T.R., Piesman J., Dolan M.C., Capiau C., Hauser P., Dequesne G., Lobet Y. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Vaccine. 13:1995;435-441.
18. Lovrich S.D., Callister S.M., DuChateau B.K., Lim L.C., Winfrey J., Day S.P., Schell R.F. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect Immun. 63:1995;2113-2119.
19. Telford S.R. I.I.I., Fikrig E., Barthold S.W., Brunet L.R., Spielman A., Flavell R.A. Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines. J Exp Med. 178:1993;755-758.
20. Philipp M.T., Lobet Y., Bohm R.P. Jr., Roberts E.D., Dennis V.A., Gu Y., Lowrie R.C. Jr., Desmons P., Duray P.H., England J.D., Hauser P., Piesman J., Xu K. The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey. Vaccine. 15:1997;1872-1887.
21. Meurice F., Parenti D., Fu D., Krause D.S. Specific issues in the design and implementation of an efficacy trial for a Lyme disease vaccine. Clin. Infect. Dis. 25:(Suppl. 1):1997;S71-S75.
22. Keller D., Koster F.T., Marks D.H., Hosbach P., Erdile L.F., Mays J.P. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA. 271:1994;1764-1768.
23. Van Hoecke C., Comberbach M., De Grave D., Desmons P., Fu D., Hauser P., Lebacq E., Lobet Y., Voet P. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Vaccine. 14:1996;1620-1626.
24. Schoen R.T., Meurice F., Brunet C.M., Cretolla S., Krause D.S., Craft J.E., Fikrig E. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis. 172:1995;1324-1329.
25. Bergstrom S., Bundoc V.G., Barbour A.G. Molecular analysis of linear plasmid-encoded major surface proteins, OpsA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol. Microbiol. 3:1989;479-486.
26. Kent PT, Kubica GP. Public Health Mycobacteriology. A guide for the Level III Laboratory. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, Georgia 30333, 1985.
27. Heifits LB, editors. Drug Susceptibility of Mycobacterial Infections. CRC Press, Boca Raton, 1991.
28. Floyd M.M., Silcox V.A., Jones W.D. Jr., Butler W.R., Kilburn J.O. Separation of Mycobacterium tuberculosis and Mycobacterium bovis by using high-performance liquid chromatography of mycolic acids. J Clin Micro Biol. 30:1992;1327-1330.
29. Taylor W.C., Aronson M.D., Delbanco T.L. Should young adults with a positive tuberculin test take isoniazide? Ann Int Med. 94:1981;808-813.
30. Hanson M.S., Cassatt D.R., Guo B.P., Patel N.K., McCarthy M.P., Dorward D.W., Hook M. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun. 66:1998;2143-2153.
31. Sadziene A., Thompson P.A., Barbour A.G. In vitro inhibition of Borrelia burgdorferi growth by antibodies. J. Infect. Dis. 167:1993;165-172.
32. Chapin K. Clinical Microbiology. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of Medical Microbiology, 6th edn. ASM Press, Washington, D.C., 1995. p. 44-46.
33. Brewer M.A., Edwards K.M., Palmer P.S., Hinson H.P. Bacille Calmette-Guérin immunization in normal healthy adults. J Infect Dis. 170:1994;476-479.
34. Kemp E.B., Belshe R.B., Hoft D.F. Immune responses stimulated by percutaneous and intradermal Bacille Calmette-Guérin. J Infect Dis. 174:1996;113-119.
35. Kalpana G.V., Bloom B.R., Jacobs W.R.Jr. Insertional mutagenesis and illegitmate recombination in mycobacteria. Proc. Natl. Acad. Sci. 88:1991;5433-5437.
36. Aldovini A., Husson, Young R.A. The μraA locus and homologous recombination in Mycobacterium bovis BCG. J. Bacteriol. 175:1993;7282-7289.
37. Snider D.E.Jr. Bacille Calmette-Guérin vaccinations and tuberculin skin tests. JAMA. 253:1985;3438-3439.
38. Sadziene A, Thompson PA, Barbour AG. Antibody responses of rats and humans to flagella-less cells and OspA protein of Borrelia burgdorferi. In: Ades EW, Morse SA, Best RF, editors. Microbial Pathogenesis and Immune Response II. Ann. N.Y. Acad. Sci., 1996. 797. p. 140-150.
39. Edelman R. Vaccines against Lyme disease. In: New Generation Vaccines. 2nd edn. eds. Levine MM, Woodrow GC, Kaper JP, Coban GS. Dekker, New York. 1997. pp. 897-912.
40. Schaible U.E., Kramer M.D., Justus C.W.E., Museteanu C., Simon M.M. Demonstration of antigen-Specific T Cells and histopathological alterations in mice experimentally inoculated with Borrelia burgdorferi. Infect Immun. 57:1989;41-47.
41. Keane-Myers A., Nickell S.P. T cell subset-dependent modulation of immunity to Borrelia burgdorferi in mice. J Immunol. 154:1995;1770-1776.
42. Lengl-Janssen B., Strauss A.F., Steere A.C., Kamradt T. The T helper cell response in Lyme arthritis: differential recognition of Borrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis. J Exp Med. 180:1994;2069-2078.
43. Zhu Y.D., Fennelly G., Miller C., Tarara R., Saxe I., Bloom B.R., McChesney M. Recombinant bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. J Infect Dis. 176:1997;1445-1453.
44. Talbot E.A., Perkins M.D., Silva S.F.M., Frothingham R. Disseminated Bacille Calmette-Guérin disease after vaccination: Case report and review. Clin Infect Dis. 24:1997;1139-1146.
45. van Deutekom H., Smulders Y.M., Roozendaal K.J., van Soolingen D. Bacille Calmette-Guérin (BCG) meningitis in an AIDS patient 12 years after vaccination with BCG. Clin Infect Dis. 22:1996;870-871.